SSY GROUP (02005.HK): 95 Varieties Included in National Essential Medicines List (2026 Edition)
NewTimeSpace News: SSY GROUP (02005.HK) announced that a total of 95 varieties (141 specifications) of the Group’s products have been incorporated into the National Essential Medicines List (2026 Edition), including 32 newly added varieties (37 specifications). The catalogue will take effect on 1 September 2026 and is expected to exert a positive impact on the Group’s growth and business development.
NewTimeSpace News: On 10 July 2026, SSY GROUP (02005.HK) released a voluntary announcement. Altogether 95 varieties (141 specifications) of the Group’s products are included in the National Essential Medicines List (2026 Edition), among which 32 varieties (37 specifications) are newly added. The products cover Glucose and Sodium Chloride Injection, Levofloxacin Sodium Chloride Injection, Sodium Bicarbonate Injection, Fluconazole Tablets, Gliclazide Tablets, Potassium Chloride Injection, Mecobalamin Injection, Azithromycin Dry Suspension and others.
The National Essential Medicines List (2026 Edition) shall be implemented on 1 September 2026. It is expected to bring positive impacts on the Group’s growth and business development.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SSY Group (02005.HK): Trustee Acquires 1 Million Shares Under Restricted Share Incentive Scheme
- SSY GROUP(02005.HK): Trustee Purchases 2 Million Shares Under Restricted Share Award Scheme at Average Price of HK$2.1585
- SSY GROUP(02005.HK): NMPA Grants Manufacturing Approval for Safinamide Mesylate Tablets and Procaterol Hydrochloride Inhalation Solution
- SSY Group(02005.HK): Trustee Purchases 380,000 Shares on Open Market Under Restricted Share Award Scheme at Average Price of HK$2.2124
- SSY Group Signs Letter of Intent with Longhai Pharma for Four Biosimilars Including Ustekinumab and Dupilumab
